Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.77 |
| ▸ | PI4KA | P42356 | 2/20 | 0.77 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.77 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.77 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.77 |
| ▸ | DPP4 | P27487 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.77 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.77 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.77 |
| ▸ | GAPDH | P04406 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.77 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.77 |
| ▸ | STAT6 | P42226 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.77 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6142045 | 1.00 | ADORA3 (0.77) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5053230 | 0.91 | ADORA3 (0.77) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23414488 | 0.91 | ADORA3 (0.77) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL4658306 | 0.91 | ADORA3 (0.77) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL26130573 | 0.91 | ADORA3 (0.77) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23050294 | 0.90 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL24538798 | 0.90 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL25936 | 0.90 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL12031327 | 0.90 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23880679 | 0.90 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 495 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240191231-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2024-06-13 | — | — | US | claimed |
| US-20220112494-A1 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | UNIVERSITY OF MASSACHUSETTS | 2022-04-14 | — | — | US | claimed |
| US-20220090071-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2022-03-24 | — | — | US | claimed |
| US-11136578-B2 | In vivo gene silencing by chemically modified and stable siRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2021-10-05 | — | — | US | claimed |
| US-11053503-B2 | Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition | KCL THERAPEUTICS, INC | 2021-07-06 | — | — | US | claimed |
| WO-2021117122-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR LYSOSOMAL ACID LIPASE DEFICIENCY SYNDROME | 株式会社リボルナバイオサイエンス | 2021-06-17 | — | — | WO | claimed |
| US-20190292540-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2019-09-26 | — | — | US | claimed |
| US-10266822-B2 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | UNIVERSITY OF MASSACHUSETTS (US) | 2019-04-23 | — | — | US | claimed |
| US-20190085328-A1 | IN VIVO SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | UNIVERSITY OF MASSACHUSETTS | 2019-03-21 | — | — | US | claimed |
| US-10087441-B2 | In vivo gene silencing by chemically modified and stable siRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2018-10-02 | — | — | US | claimed |
| WO-2004029212-A2 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2004-04-08 | — | — | WO | claimed |
| US-6509460-B1 | Contacting the modified nucleotide triphosphate with a mixture comprising a nucleic acid template, an RNA polymerase enzyme, and an enhancer of modified nucleotide triphosphate incorporation | RIBOZYME PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | claimed |
| US-20020193314-A1 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | MITSUI CHEMICALS, INC. (JP) | 2002-12-19 | — | — | US | claimed |
| EP-1212416-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| JP-2002512794-A | — | — | 2002-05-08 | — | — | JP | claimed |
| EP-1178051-A2 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2002-02-06 | — | — | EP | claimed |
| WO-2001016312-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| EP-1073732-A2 | NUCLEOSIDE TRIPHOSPHATES AND THEIR INCORPORATION INTO RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-02-07 | — | — | EP | claimed |
| US-6127535-A | FOR THE INCORPORATION OF MODIFIED (NON-STANDARD) AND UNMODIFIED NUCLEOTIDES INTO NUCLEIC ACIDS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | claimed |
| WO-1999055857-A2 | NUCLEOSIDE TRIPHOSPHATES AND THEIR INCORPORATION INTO RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-11-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190085328-A1 | IN VIVO SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | AGO2, SNRPE, NSUN2 | ADORA3 1619/4885ADORA1 2263/4885PI4KA 3107/4885 |
| US-20220112494-A1 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | SNRPE, AGO2, NSUN2 | ADORA3 2303/4885ADORA1 3051/4885PI4KA 3628/4885 |
| US-20020193314-A1 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | PNP, GALE, MTAP | ADORA3 544/4885ADORA1 308/4885PI4KA 508/4885 |
| US-11136578-B2 | In vivo gene silencing by chemically modified and stable siRNA | SNRPE, AGO2, NSUN2 | ADORA3 2303/4885ADORA1 3051/4885PI4KA 3628/4885 |
| US-10087441-B2 | In vivo gene silencing by chemically modified and stable siRNA | SNRPE, AGO2, NSUN2 | ADORA3 2303/4885ADORA1 3051/4885PI4KA 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.